Bioxytran Income Statement

Financials in millions USD. Fiscal year is January - December.

Millions USD. Fiscal year is Jan - Dec.

Fiscal Year	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Period Ending	Dec '25 Dec 31, 2025	Dec '24 Dec 31, 2024	Dec '23 Dec 31, 2023	Dec '22 Dec 31, 2022	Dec '21 Dec 31, 2021
Selling, General & Admin	1.39	2.11	2.65	1.16	2.2
Research & Development	0.45	0.11	1.15	0.98	2.01
Amortization of Goodwill & Intangibles	0.01	0.01	0.01	0	-
Operating Expenses	1.85	2.23	3.81	2.14	4.21
Operating Income	-1.85	-2.23	-3.81	-2.14	-4.21
Interest Expense	-0.19	-0.77	-0.75	-0.52	-0.31
Other Non Operating Income (Expenses)	-0.22	0.13	-	-	-
EBT Excluding Unusual Items	-2.26	-2.87	-4.56	-2.66	-4.53
Other Unusual Items	0.13	0.49	-	-	-
Pretax Income	-2.12	-2.38	-4.56	-2.66	-4.53
Earnings From Continuing Operations	-2.12	-2.38	-4.56	-2.66	-4.53
Minority Interest in Earnings	-	0.01	0.09	0.19	0.5
Net Income	-2.12	-2.37	-4.47	-2.46	-4.03
Net Income to Common	-2.12	-2.37	-4.47	-2.46	-4.03
Shares Outstanding (Basic)	92	139	134	115	106
Shares Outstanding (Diluted)	92	139	134	115	106
Shares Change (YoY)	-33.73%	3.45%	16.13%	8.57%	13.07%
EPS (Basic)	-0.02	-0.02	-0.03	-0.02	-0.04
EPS (Diluted)	-0.02	-0.02	-0.03	-0.02	-0.04
EBITDA	-1.84	-2.22	-3.8	-2.13	-
D&A For EBITDA	0.01	0.01	0.01	0	-
EBIT	-1.85	-2.23	-3.81	-2.14	-4.21

Source: S&P Global Market Intelligence. Standard template. Financial Sources.